| Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence D Candotti, CK Lin, D Belkhiri, T Sakuldamrongpanich, S Biswas, S Lin, ... Gut 61 (12), 1744-1753, 2012 | 134 | 2012 |
| In vitro probiotic characterization of Lactobacillus casei isolated from marine samples P Das, S Khowala, S Biswas Lwt 73, 383-390, 2016 | 88 | 2016 |
| Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus HJ Field, S Biswas Drug Resistance Updates 14 (1), 45-51, 2011 | 76 | 2011 |
| Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection S Biswas, D Candotti, JP Allain Journal of Virology 87 (14), 7882-7892, 2013 | 64 | 2013 |
| The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1 S Biswas, L Jennens, HJ Field Antiviral research 75 (1), 30-35, 2007 | 63 | 2007 |
| Herpesvirus latency and therapy—from a veterinary perspective HJ Field, S Biswas, IT Mohammad Antiviral research 71 (2-3), 127-133, 2006 | 50 | 2006 |
| Herpes Simplex Virus Helicase—Primase Inhibitors: Recent Findings from the Study of Drug Resistance Mutations S Biswas, HJ Field Antiviral Chemistry and Chemotherapy 19 (1), 1-6, 2008 | 47 | 2008 |
| Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1 S Biswas, C Smith, HJ Field Journal of antimicrobial chemotherapy 60 (2), 274-279, 2007 | 43 | 2007 |
| High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1 S Biswas, M Swift, HJ Field Antiviral Chemistry and Chemotherapy 18 (1), 13-23, 2007 | 43 | 2007 |
| A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target S Biswas, G Kleymann, M Swift, LS Tiley, J Lyall, J Aguirre-Hernandez, ... Journal of antimicrobial chemotherapy 61 (5), 1044-1047, 2008 | 42 | 2008 |
| Mismatch primer-based PCR reveals that helicase–primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during … S Sukla, S Biswas, A Birkmann, P Lischka, H Zimmermann, HJ Field Journal of antimicrobial chemotherapy 65 (7), 1347-1352, 2010 | 39 | 2010 |
| Comparative genomics of serotype Asia 1 foot-and-mouth disease virus isolates from India sampled over the last two decades JK Mohapatra, A Sanyal, D Hemadri, C Tosh, S Biswas, NJ Knowles, ... Virus research 136 (1-2), 16-29, 2008 | 39 | 2008 |
| Archived dengue serum samples produced false-positive results in SARS-CoV-2 lateral flow-based rapid antibody tests H Nath, A Mallick, S Roy, S Sukla, K Basu, A De, S Biswas Journal of Medical Microbiology 70 (6), 001369, 2021 | 38 | 2021 |
| Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased … S Biswas, L Jennens, HJ Field Archives of virology 152, 1489-1500, 2007 | 38 | 2007 |
| Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID … H Nath, A Mallick, S Roy, S Sukla, S Biswas Computational and Structural Biotechnology Journal 19, 459-466, 2021 | 37 | 2021 |
| A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to … S Biswas, RN Miguel, S Sukla, HJ Field Journal of general virology 90 (8), 1937-1942, 2009 | 30 | 2009 |
| Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase–primase inhibitors, variously affect virus growth rate and pathogenicity S Biswas, LS Tiley, H Zimmermann, A Birkmann, HJ Field Antiviral research 80 (1), 81-85, 2008 | 27 | 2008 |
| Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both … H Nath, A Mallick, S Roy, S Sukla, K Basu, A De, S Biswas MedRxiv, 2020.07. 03.20145797, 2020 | 24 | 2020 |
| Leptomonas seymouri narna-like virus 1 and not leishmaniaviruses detected in kala-azar samples from India S Sukla, S Roy, S Sundar, S Biswas Archives of Virology (Online text-only view available under Springer Nature …, 2017 | 24 | 2017 |
| Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant S Sukla, S Biswas, A Birkmann, P Lischka, H Ruebsamen-Schaeff, ... Antiviral research 87 (1), 67-73, 2010 | 22 | 2010 |
